Poulpharm supports key stages in the development and registration of veterinary medicines and vaccines, feed additives and other feed products.

During development, a proof-of-concept study can assess a product’s potential, from initial efficacy to investigation of its mechanism of action. Our scientific team can help select and design an appropriate study model for the research question.

For registration, pivotal efficacy and safety studies can be designed and conducted under the applicable regulatory and quality requirements. Study Directors, laboratory technicians and animal-care personnel work to the approved protocol, with agreed regulatory support for study documentation and reporting.

Following registration, Poulpharm can also coordinate market-support and real-world field studies under a predefined protocol. These studies can complement controlled facility trials by generating evidence under commercial conditions. Any use of study results should remain consistent with the product’s authorised claims.

Housing types

Depending on the study objective, Poulpharm can coordinate controlled in vivo studies in poultry, rabbits and pigs across facilities suited to projects of different scales.

Facilities include:

• Floor pens (Poultry, rabbits and pigs)
• Controlled experimental cage housing for poultry
• Controlled pig research housing
• Specialised containment cages for poultry
• BSL-2 and BSL-3 isolators for poultry
• HEPA-filtered isolator rooms for floor-pen or pig studies
• Large-scale controlled poultry compartments
• Grower-finisher pig housing

Through a vetted network of farms, veterinary practices and research partners in selected markets across Europe, Asia and Latin America, Poulpharm can coordinate real-world field studies tailored to the target species and approved protocol. Partner locations and capabilities are confirmed for each project.

Poulpharm offers a range of study models for veterinary medicines and vaccines, feed additives, other feed products and, where applicable, biocides. Availability and regulatory scope are confirmed for each project:

• Efficacy studies
• Dose-determination studies
• Target animal safety studies
• Product, formulation or co-administration compatibility studies, as defined in the protocol
• Toxicity studies
• Tissue-residue depletion studies
• Pharmacokinetic studies

Subject to confirmation for the target species and study design, our scientific team can support the following disease and challenge models:

• Parasitic disease and challenge models
  • Coccidiosis
  • Histomoniasis
  • Helminth infections
  • Red blood mites
  • …
• Bacterial disease and challenge models
  • Necrotic enteritis
  • Bacterial enteritis
  • E. coli
  • Salmonellosis
  • Mycoplasma
  • Gallibacterium
  • Enterococcus
  • Streptococcus
  • Staphylococcus
  • …
• Viral disease and challenge models
  • Infectious laryngotracheitis
  • Infectious bronchitis
  • Marek’s disease
  • Adenovirus-associated disease models
  • Reovirus-associated disease models
  • Fowlpox
  • Avian metapneumovirus infection
  • Avian encephalomyelitis
  • Swine influenza
  • Porcine reproductive and respiratory syndrome
  • …

Non-infectious and performance models include:

• Nutritional and performance studies
• Non-infectious challenge models: lipopolysaccharide (LPS), heat stress and mycotoxin challenge
• Welfare and locomotion models: footpad dermatitis and lameness
• Intestinal-barrier models

Samples collected during in vivo studies can be analysed in our laboratories or, where appropriate, by qualified partner laboratories selected for the required method and quality framework.

• Bacteriology 
• Parasitology 
• Virology 
• Serology 
• Molecular diagnostics (PCR)  
• Histo-pathology